ESMO 2021 | Improved OS in men with de novo metastatic castration-sensitive prostate cancer
PEACE-1 is a phase 3 trial of abiraterone acetate plus abiraterone and/or local radiotherapy for treatment of men with de novo metastatic castration-sensitive prostate cancer. In this MEDtalk, Karim Fizazi, MD, PhD, medical oncologist at Gustave Roussy, professor in Oncology at the University of Paris-Saclay in Villejuif, France, presents the result of PEACE-1 and explain how the combination improves both rPFS and OS.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.